Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

YoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness

In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.

Read more

Great new opportunity for the YoungEHA community!

Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee

The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…

Read more

YoungEHA

Welcome to YoungEHA!As a junior member of EHA, you are part of the YoungEHA family.

Read more

EHA-EBMT 2nd European CAR T Cell Meeting

Dates:             January 30 – February 1, 2020
Location:        Sitges (Barcelona), Spain
Chairs:            H Einsele, C Chabannon

The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…

Read more